Non Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients Scheduled for Electrical Cardioversion: A Real-Life Propensity Score Matched Study

References

• Airaksinen KE, Grönberg T, Nuotio I, et al. Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study. J Am Coll Cardiol. 2013;62(13):1187–1192. doi:10.1016/j.jacc.2013.04.089
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Eng J Med. 2009;361(12):1139–1151. doi:10.1056/NEJMoa0905561
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–2104. doi:10.1056/NEJMoa1310907
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Eng J Med. 2011;365(11):981–992. doi:10.1056/NEJMoa1107039
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Eng J Med. 2011;365(10):883–891. doi:10.1056/NEJMoa1009638
   PubMed Web of Science ®Google Scholar
• Russo V, Bianchi V, Cavallaro C, et al. Efficacy and safety of dabigatran in a “real-life” population at high thromboembolic and hemorrhagic risk: data from MonaldiCare registry. Eur Rev Med Pharmacol Sci. 2015;19(20):3961–3967.
   PubMed Web of Science ®Google Scholar
• Russo V, Rago A, Proietti R, et al. Efficacy and safety of the target-specific oral anticoagulants for stroke prevention in atrial fibrillation: the real-life evidence. Ther Adv Drug Saf. 2017;8(2):67–75. doi:10.1177/2042098616673990
   Web of Science ®Google Scholar
• Russo V, Rago A, D’Onofrio A, et al. The clinical performance of dabigatran in the Italian real-life experience. J Cardiovasc Med. 2017;18(11):922–923. doi:10.2459/JCM.0000000000000548
   Google Scholar
• Proietti R, Joza J, Arensi A, et al. Novel nonpharmacologic approaches for stroke prevention in atrial fibrillation: results from clinical trials. Med Devices. 2015;8:103–114. doi:10.2147/MDER.S70672
   Google Scholar
• Melillo E, Carbone A, Rago A, et al. Update on Direct Oral Anticoagulants in Atrial Fibrillation Patients Undergoing Cardiac Interventional Procedures: from Clinical Trials to Real-World Evidence. J Cardiovasc Pharmacol. 2020;75(3):185–199. doi:10.1097/FJC.0000000000000786
   Web of Science ®Google Scholar
• Russo V, Carbone A, Rago A, et al. Direct Oral Anticoagulants in Octogenarians With Atrial Fibrillation: it Is Never Too Late. J Cardiovasc Pharmacol. 2019;73(4):207–214. doi:10.1097/FJC.0000000000000661
   PubMed Web of Science ®Google Scholar
• Russo V, Bottino R, Rago A, et al. Atrial Fibrillation and Malignancy: the Clinical Performance of Non-Vitamin K Oral Anticoagulants-A Systematic Review. Semin Thromb Hemost. 2019;45(2):205–214. doi:10.1055/s-0038-1661386
   PubMed Web of Science ®Google Scholar
• Russo V, Bottino R, Rago A, et al. Clinical Performance of Nonvitamin K Antagonist Oral Anticoagulants in Real-World Obese Patients with Atrial Fibrillation. Semin Thromb Hemost. 2020;46(8):970–976. doi:10.1055/s-0040-1715792
   PubMed Web of Science ®Google Scholar
• Russo V, Paccone A, Rago A, et al. Apixaban in a Morbid Obese Patient with Atrial Fibrillation: a Clinical Experience Using the Plasmatic Drug Evaluation. J Blood Med. 2020;11:77–81. doi:10.2147/JBM.S229526
   PubMed Web of Science ®Google Scholar
• Russo V, Rago A, Papa A, et al. Use of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients with Malignancy: clinical Practice Experience in a Single Institution and Literature Review. Semin Thromb Hemost. 2018;44(4):370–376. doi:10.1055/s-0037-1607436
   Web of Science ®Google Scholar
• Russo V, Attena E, Mazzone C, et al. Nonvitamin K Antagonist Oral Anticoagulants Use in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves/Prior Surgical Valve Repair: a Multicenter Clinical Practice Experience. Semin Thromb Hemost. 2018;44(4):364–369. doi:10.1055/s-0037-1615261
   Web of Science ®Google Scholar
• Russo V, Carbone A, Attena E, et al. Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves. Clin Ther. 2019;41(12):2549–2557. doi:10.1016/j.clinthera.2019.10.008
   PubMed Web of Science ®Google Scholar
• Russo V, Attena E, Mazzone C, et al. Real-life Performance of Edoxaban in Elderly Patients With Atrial Fibrillation: a Multicenter Propensity Score-Matched Cohort Study. Clin Ther. 2019;41(8):1598–1604. doi:10.1016/j.clinthera.2019.04.041
   Web of Science ®Google Scholar
• Russo V, Attena E, Rago A, et al. Clinical Outcome of Edoxaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation and Diabetes Mellitus: results from a Multicenter, Propensity-Matched, Real-World Cohort Study. J Clin Med. 2020;9(6):1621. doi:10.3390/jcm9061621
   Web of Science ®Google Scholar
• Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011;123(2):131–136. doi:10.1161/CIRCULATIONAHA.110.977546
   PubMed Web of Science ®Google Scholar
• Piccini JP, Stevens SR, Lokhnygina Y, et al. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol. 2013;61(19):1998–2006. doi:10.1016/j.jacc.2013.02.025
   PubMed Web of Science ®Google Scholar
• Flaker G, Lopes RD, Al-Khatib SM, et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol. 2014;63(11):1082–1087. doi:10.1016/j.jacc.2013.09.062
   PubMed Web of Science ®Google Scholar
• Plitt A, Ezekowitz MD, De Caterina R, et al. Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48. Clin Cardiol. 2016;39(6):345–346. doi:10.1002/clc.22537
   PubMed Web of Science ®Google Scholar
• Cappato R, Ezekowitz MD, Klein AL, et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014;35(47):3346–3355. doi:10.1093/eurheartj/ehu367
   PubMed Web of Science ®Google Scholar
• Goette A, Merino JL, Ezekowitz MD, et al. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet. 2016;388(10055):1995–2003. doi:10.1016/S0140-6736(16)31474-X
   PubMed Web of Science ®Google Scholar
• Ezekowitz MD, Pollack CV, Sanders P, et al. Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: rationale and design of the EMANATE trial. Am Heart J. 2016;179:59–68. doi:10.1016/j.ahj.2016.06.008
   PubMed Web of Science ®Google Scholar
• Steffel J, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330–1393.
   PubMed Web of Science ®Google Scholar
• Hindricks G, et al. ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020;42(5):373–498.
   Web of Science ®Google Scholar
• Russo V, Rago A, Papa AA, et al. Efficacy and safety of dabigatran in patients with atrial fibrillation scheduled for transoesophageal echocardiogram-guided direct electrical current cardioversion: a prospective propensity score-matched cohort study. J Thromb Thrombolysis. 2018;45(2):206–212. doi:10.1007/s11239-017-1599-5
   Web of Science ®Google Scholar
• Rago A, Papa AA, Cassese A, et al. Clinical Performance of Apixaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation Undergoing Direct Electrical Current Cardioversion: a Prospective Propensity Score-Matched Cohort Study. Am J Cardiovasc Drugs. 2019;19(4):421–427. doi:10.1007/s40256-019-00341-9
   Web of Science ®Google Scholar
• Rago A, Papa AA, Attena E, et al. Direct Current Cardioversion in Atrial Fibrillation Patients on Edoxaban Therapy Versus Vitamin K Antagonists: a Real-world Propensity Score-Matched Study. Cardiovasc Drugs Ther. 2020. doi:10.1007/s10557-020-07078-7
   Web of Science ®Google Scholar
• Stabile G, Russo V, Rapacciuolo A, et al. Transesophageal echocardiograpy in patients with persistent atrial fibrillation undergoing electrical cardioversion on new oral anticoagulants: a multi center registry. Int J Cardiol. 2015;184:283–284. doi:10.1016/j.ijcard.2015.02.075
   Web of Science ®Google Scholar
• Bertaglia E, Anselmino M, Zorzi A, et al. NOACs and atrial fibrillation: incidence and predictors of left atrial thrombus in the real world. Int J Cardiol. 2017;249:179–183. doi:10.1016/j.ijcard.2017.07.048
   PubMed Web of Science ®Google Scholar
• Kaatz S, Ahmad D, Spyropoulos AC, et al. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. 2015;13(11):2119–2126. doi:10.1111/jth.13140
   PubMed Web of Science ®Google Scholar
• Telles-Garcia N, Dahal K, Kocherla C, et al. Non-vitamin K antagonists oral anticoagulants are as safe and effective as warfarin for cardioversion of atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol. 2018;268:143–148. doi:10.1016/j.ijcard.2018.04.034
   Web of Science ®Google Scholar
• Brunetti ND, Tarantino N, De Gennaro L, et al. Direct oral anti-coagulants compared to vitamin-K antagonists in cardioversion of atrial fibrillation: an updated meta-analysis. J Thromb Thrombolysis. 2018;45(4):550–556. doi:10.1007/s11239-018-1622-5
   Web of Science ®Google Scholar
• Kotecha D, Pollack CV, De Caterina R, et al. Direct Oral Anticoagulants Halve Thromboembolic Events After Cardioversion of AF Compared With Warfarin. J Am Coll Cardiol. 2018;72(16):1984–1986. doi:10.1016/j.jacc.2018.07.083
   Web of Science ®Google Scholar
• Verdecchia P, D’Onofrio A, Russo V, et al. Persistence on apixaban in atrial fibrillation patients: a retrospective multicentre study. J Cardiovasc Med. 2019;20(2):66–73. doi:10.2459/JCM.0000000000000744
   Google Scholar